Clinical Trial Update: Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of GSK Boostrix (Tdap) in adults 19–64; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acellular Pertussis
• Diphtheria
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Diphtheria | Phase 3 | Status: COMPLETED | Results posted: 2018-08-07